|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Atea Pharmaceuticals, Inc. (AVIR) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,620,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Co. is focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus that causes COVID-19, hepatitis C virus, or HCV, dengue virus, and respiratory syncytial virus, or RSV.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
25,000 |
25,000 |
25,000 |
| Total Buy Value |
$0 |
$81,499 |
$81,499 |
$81,499 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
25,000 |
442,575 |
588,073 |
| Total Sell Value |
$0 |
$81,499 |
$1,339,128 |
$1,892,230 |
| Total People Sold |
0 |
1 |
2 |
8 |
| Total Sell Transactions |
0 |
2 |
6 |
14 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Murphy Polly A. |
|
– • – |
2025-06-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,600 |
86,045 |
|
- |
|
| Lucidi Bruno |
|
– • – |
2025-06-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,600 |
112,750 |
|
- |
|
| Berger Franklin M |
|
– • – |
2025-06-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,600 |
506,497 |
|
- |
|
| Polsky Bruce |
|
– • – |
2025-06-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,600 |
95,206 |
|
- |
|
| Duncan Barbara Gayle |
|
– • – |
2025-06-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,600 |
62,750 |
|
- |
|
| Adams Jerome M. |
|
– • – |
2025-06-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
29,600 |
62,750 |
|
- |
|
| Kirsch Arthur S |
|
– • – |
2025-02-20 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
10,000 |
|
- |
|
| Kirsch Arthur S |
|
– • – |
2025-02-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,710 |
|
- |
|
| Vavricka John |
Chief Commercial Officer |
• – – |
2025-01-31 |
4 |
D |
$3.06 |
$35,242 |
D/D |
(11,517) |
52,081 |
|
- |
|
| Vavricka John |
Chief Commercial Officer |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
63,598 |
|
- |
|
| Vavricka John |
Chief Commercial Officer |
• – – |
2025-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,333 |
54,848 |
|
- |
|
| Hammond Janet Mj |
Chief Development Officer |
• – – |
2025-01-31 |
4 |
D |
$3.06 |
$43,250 |
D/D |
(14,134) |
81,388 |
|
- |
|
| Hammond Janet Mj |
Chief Development Officer |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
11,250 |
95,522 |
|
- |
|
| Hammond Janet Mj |
Chief Development Officer |
• – – |
2025-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
46,800 |
84,272 |
|
- |
|
| Foster Wayne |
EVP, Chief Accounting Officer |
• – – |
2025-01-31 |
4 |
D |
$3.06 |
$36,910 |
D/D |
(12,062) |
50,128 |
|
- |
|
| Foster Wayne |
EVP, Chief Accounting Officer |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
62,190 |
|
- |
|
| Foster Wayne |
EVP, Chief Accounting Officer |
• – – |
2025-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,333 |
54,190 |
|
- |
|
| Sommadossi Jean-Pierre |
President, CEO, and Chairman |
• • – |
2025-01-31 |
4 |
D |
$3.06 |
$271,119 |
D/D |
(88,601) |
300,940 |
|
- |
|
| Sommadossi Jean-Pierre |
President, CEO, and Chairman |
• • – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
99,517 |
389,541 |
|
- |
|
| Sommadossi Jean-Pierre |
President, CEO, and Chairman |
• • – |
2025-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
173,467 |
290,024 |
|
- |
|
| Corcoran Andrea |
See Remarks |
• – – |
2025-01-31 |
4 |
D |
$3.06 |
$49,272 |
D/D |
(16,102) |
717,307 |
|
- |
|
| Corcoran Andrea |
See Remarks |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
733,409 |
|
- |
|
| Corcoran Andrea |
See Remarks |
• – – |
2025-01-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
44,367 |
722,909 |
|
- |
|
| Horga Maria Arantxa |
Chief Medical Officer |
• – – |
2025-01-31 |
4 |
D |
$3.06 |
$49,177 |
D/D |
(16,071) |
60,876 |
|
- |
|
| Horga Maria Arantxa |
Chief Medical Officer |
• – – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
9,750 |
76,947 |
|
- |
|
75 Records found
|
|
Page 1 of 3 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
